Back to News
Market Impact: 0.15
Clearmind Medicine Briefs FDA On Patient Access At Psychedelic Hearing
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Clearmind Medicine said Chief of Global Impact Mary-Elizabeth Gifford testified at an FDA hearing in Washington, D.C. on September 14, 2026, concerning the potential future therapeutic use of psychedelic drugs. The announcement signals engagement in the evolving regulatory discussion but provides no clinical, financial, or FDA approval outcome.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
CMND0.20
More News
- UN mission finds evidence of U.S. war crimes in Iran; Washington rejects report
- California AG Bonta on Paramount-Warner Bros., Meta and AI
- UK Lawmakers Say Thames Creditors Have Been Joyriding Family Car
- Warsh spooks investors, OpenAI's 'concerning' incidents, Boeing's production problems and more in Morning Squawk
- AI coding agents' 0-click RCE flaw could hand attackers keys to the kingdom
- What an Oscar-winning movie can teach us about investing through the AI slowdown debate